How to buy Genocea Biosciences stock (GNCA)

Genocea Biosciences is a biotechnology & medical research business based in the US. Genocea Biosciences shares (GNCA) are listed on the NASDAQ and all prices are listed in US Dollars. Genocea Biosciences employs 74 staff and has a trailing 12-month revenue of around $1.9 million.

Our top picks for where to buy Genocea Biosciences stock

Buy Genocea Biosciences stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Genocea Biosciences stock price (NASDAQ: GNCA)

Use our graph to track the performance of GNCA stocks over time.

Genocea Biosciences shares at a glance

• Key figures

Information last updated 2023-04-02.

52-week range	$0.00 - $0.00
50-day moving average more info button	$0.00
200-day moving average more info button	$0.11
Wall St. target price	$3.08
PE ratio more info button	N/A
Dividend yield more info button	$0 (0%)
Earnings per share (TTM) more info button	$-0.53

Is it a good time to buy Genocea Biosciences stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Genocea Biosciences financials

Revenue TTM	$1.9 million
Gross profit TTM	$1.6 million
Return on assets TTM	-57.59%
Return on equity TTM	-525.78%
Profit margin	0%
Book value	$0.21
Market Capitalization more info button	$5,878

TTM: trailing 12 months

Genocea Biosciences share dividends

We're not expecting Genocea Biosciences to pay a dividend over the next 12 months.

Have Genocea Biosciences's shares ever split?

Genocea Biosciences's shares were split on a 1:8 basis on 21 May 2019 . So if you had owned 8 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Genocea Biosciences shares – just the quantity. However, indirectly, the new 700% higher share price could have impacted the market appetite for Genocea Biosciences shares which in turn could have impacted Genocea Biosciences's share price.

Genocea Biosciences share price volatility

Over the last 12 months, Genocea Biosciences's shares have ranged in value from as little as $0 up to $0. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Genocea Biosciences's is 1.6038. This would suggest that Genocea Biosciences's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Genocea Biosciences overview

Genocea Biosciences, Inc. , a biopharmaceutical company, discovers and develops novel cancer immunotherapies. The company uses its proprietary discovery platform, ATLAS, which profiles each patient's CD4+ and CD8+ T cell immune responses to every target or antigen identified by next-generation sequencing of that patient's tumor. Its products include GEN-011, an adoptive T cell therapy, which is in Phase 1/2a clinical trials for the treatment of solid tumors; and GEN-009, a neoantigen vaccine candidate, which is in Phase 1/2a clinical trials that delivers adjuvanted synthetic long peptides spanning ATLAS-identified anti-tumor neoantigens. The company was incorporated in 2006 and is based in Cambridge, Massachusetts. On July 5, 2022, Genocea Biosciences, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.

Frequently asked questions

null
What percentage of Genocea Biosciences is owned by insiders or institutions?
Currently 6.222% of Genocea Biosciences shares are held by insiders and 1.249% by institutions. How many people work for Genocea Biosciences?
Latest data suggests 74 work at Genocea Biosciences. When does the fiscal year end for Genocea Biosciences?
Genocea Biosciences's fiscal year ends in December. Where is Genocea Biosciences based?
Genocea Biosciences's address is: 100 Acorn Park Drive, Cambridge, MA, United States, 02140 What is Genocea Biosciences's ISIN number?
Genocea Biosciences's international securities identification number is: US3724274010 What is Genocea Biosciences's CUSIP number?
Genocea Biosciences's Committee on Uniform Securities Identification Procedures number is: 372427401